News
11 October 2013
Correlation demonstrated between cognitive performance assessed with CANTAB schizophrenia battery and MCCB in Phase 2 clinical trials
Cambridge Cognition presents a comparison of the Cantab schizophrenia battery and the MCCB at the International Society for CNS Clinical Trials and Methodology Autumn conference.
Cambridge Cognition presents a comparison of the Cantab schizophrenia battery and the MCCB at the International Society for CNS Clinical Trials and Methodology Autumn conference.
The MATRICS consensus cognitive battery (MCCB) was developed as a consensus approach to testing cognition in clinical trials of cognitive impairments associated with schizophrenia (CIAS). The battery, presented in a mostly pencil-and-paper format, contains ten tests covering seven cognitive domains known to be affected by schizophrenia. The Cantab schizophrenia battery includes eight computerised neuropsychological tests presented on a touch screen computer and selected to assess the same seven domains covered by the MCCB.
This study evaluated the relationship between the MATRICS and Cantab schizophrenia batteries in the baseline evaluations of two Phase 2 clinical trials. We found that summary scores of cognitive performance assessed by the two batteries were well correlated, and both batteries showed a moderate association with functional capacity as measured by the UPSA-2.
To find out more about using the Cantab batteries for clinical trials contact us.